Assessment of Efficacy and Safety of Metabolic Therapy With Trimetazidine MB in Patients With Ischemic Heart Disease and Chronic Heart Failure

Горбунова, Мария Лавровна; Vilkova, A.V. Vilkova

doi:10.18565/cardio.2016.3.67-72

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six studies (21%) were conducted in Russia and not reported in English. [23][24][25][26][27][28] Only two studies were conducted after the latest major revision of the European Society of Cardiology (ESC) HF guidelines in 2021, which explains the limited HF-background therapy (table 1, online supplemental table A3).…”

Section: Search Resultsmentioning

confidence: 99%

Effects of trimetazidine on heart failure with reduced ejection fraction and associated clinical outcomes: a systematic review and meta-analysis

Nassiri,

Van de Bovenkamp,

Remmelzwaal

et al. 2024

Open Heart

View full text Add to dashboard Cite

BackgroundDespite maximal treatment, heart failure (HF) remains a major clinical challenge. Besides neurohormonal overactivation, myocardial energy homoeostasis is also impaired in HF. Trimetazidine has the potential to restore myocardial energy status by inhibiting fatty acid oxidation, concomitantly enhancing glucose oxidation. Trimetazidine is an interesting adjunct treatment, for it is safe, easy to use and comes at a low cost.ObjectiveWe conducted a systematic review to evaluate all available clinical evidence on trimetazidine in HF. We searched Medline/PubMed, Embase, Cochrane CENTRAL and ClinicalTrials.gov to identify relevant studies.MethodsOut of 213 records, we included 28 studies in the meta-analysis (containing 2552 unique patients), which almost exclusively randomised patients with HF with reduced ejection fraction (HFrEF). The studies were relatively small (median study size: N=58) and of short duration (mean follow-up: 6 months), with the majority (68%) being open label.ResultsTrimetazidine in HFrEF was found to significantly reduce cardiovascular mortality (OR 0.33, 95% CI 0.21 to 0.53) and HF hospitalisations (OR 0.42, 95% CI 0.29 to 0.60). In addition, trimetazidine improved (New York Heart Association) functional class (mean difference: −0.44 (95% CI −0.49 to −0.39), 6 min walk distance (mean difference: +109 m (95% CI 105 to 114 m) and quality of life (standardised mean difference: +0.52 (95% CI 0.32 to 0.71). A similar pattern of effects was observed for both ischaemic and non-ischaemic cardiomyopathy.ConclusionsCurrent evidence supports the potential role of trimetazidine in HFrEF, but this is based on multiple smaller trials of varying quality in study design. We recommend a large pragmatic randomised clinical trial to establish the definitive role of trimetazidine in the management of HFrEF.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Effects of trimetazidine on heart failure with reduced ejection fraction and associated clinical outcomes: a systematic review and meta-analysis

Nassiri,

Van de Bovenkamp,

Remmelzwaal

et al. 2024

Open Heart

View full text Add to dashboard Cite

show abstract

“…Cardiac fuel substrate selection is dynamic and may differ according to prevailing physiological or pathophysiological conditions. Several recent studies have shown that metabolic therapy can be a potential and promising approach in dealing with IHD and heart failure (Gorbunova and Vilkova, 2016). Glucose oxidation is a major contributor to overall cardiac metabolism and myocardial glucose oxidation is perturbed during the progression of a variety of cardiovascular diseases, including ischemic heart disease, diabetic cardiomyopathy, and heart failure (Jaswal et al, 2011;Zlobine et al, 2016).…”

Section: Impact Of Foxo1 Post-translational Status On Heart Metabolismmentioning

confidence: 99%

Metabolic aspects of cardiovascular diseases: Is FoxO1 a player or a target?

Menghini

Casagrande

Iuliani

et al. 2020

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

Role of Chinese Herbal Medicines in Regulation of Energy Metabolism in Treating Cardiovascular Diseases

Guan

2019

Chin. J. Integr. Med.

View full text Add to dashboard Cite

Assessment of Efficacy and Safety of Metabolic Therapy With Trimetazidine MB in Patients With Ischemic Heart Disease and Chronic Heart Failure

Cited by 3 publications

References 0 publications

Effects of trimetazidine on heart failure with reduced ejection fraction and associated clinical outcomes: a systematic review and meta-analysis

Effects of trimetazidine on heart failure with reduced ejection fraction and associated clinical outcomes: a systematic review and meta-analysis

Metabolic aspects of cardiovascular diseases: Is FoxO1 a player or a target?

Role of Chinese Herbal Medicines in Regulation of Energy Metabolism in Treating Cardiovascular Diseases

Contact Info

Product

Resources

About